NeuroPace, Inc.

83 articles about NeuroPace, Inc.

• NeuroPace to Present at the Needham 23rd Annual Healthcare Conference

  3/27/2024

  NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will present at the Needham 23rd Annual Healthcare Conference, taking place virtually from April 8-11.

• NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million

  3/5/2024

  NeuroPace, Inc., a medical device company focused on transforming the lives of people living with epilepsy, reported financial results for the fourth quarter and full year ended December 31, 2023.

• NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

  2/15/2024

  NeuroPace, Inc. announced it will report financial results for the fourth quarter and full year 2023 after market close on Tuesday, March 5, 2024.

• NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates

  1/8/2024

  NeuroPace, Inc. announced preliminary unaudited revenue for the quarter and year ended December 31, 2023 and provided business updates.

• NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study

  12/21/2023

  NeuroPace, Inc. (Nasdaq: NPCE), a commercial, growth-stage, medical technology company focused on transforming the lives of people living with epilepsy, today announced the completion of the patient enrollment goal in its NAUTILUS pivotal study for the treatment of idiopathic generalized epilepsy (IGE) more than one quarter ahead of schedule.

• NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference

  12/19/2023

  NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference at 7:30am PT (10:30am ET) on Thursday, January 10, 2024, in San Francisco, CA.

• NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration

  12/4/2023

  NeuroPace, Inc. (Nasdaq: NPCE), a growth-stage medical technology company focused on transforming the lives of people living with epilepsy, today announced a first of its kind strategic collaboration that will leverage RNS System’s unique biomarker monitoring and data analysis capabilities.

• NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting

  12/1/2023

  NeuroPace, Inc. today announced that the Company will have a substantial presence at the 77th American Epilepsy Society Annual Meeting (AES 2023), to be held in Orlando, Florida and virtually from December 1-5, 2023.

• NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference

  11/21/2023

  NeuroPace, Inc. today announced will present at the Piper Sandler 35th Annual Healthcare Conference, taking place November 28-30 in New York, NY.

• NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

  11/6/2023

  NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the third quarter ended September 30, 2023.

• NeuroPace Announces RNS System Enhancements Designed to Streamline Care

  10/17/2023

  NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, announced a series of key enhancements to its RNS System, all designed to streamline care.

• NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023

  10/16/2023

  NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2023 after market close on Monday November 6, 2023.

• NeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare Conference

  9/20/2023

  NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced participation in a fireside chat discussion at the upcoming 2023 Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023, at 1:15 p.m. ET in New York, New York.

• NeuroPace to Participate in Upcoming September 2023 Investor Conferences

  8/24/2023

  NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, announced its participation in the following upcoming investor conferences:

• NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

  8/8/2023

  NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, reported financial results for the second quarter ended June 30, 2023.

• NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market - July 19, 2023

  7/19/2023

  NeuroPace, Inc. announced that it granted to Joel Becker, NeuroPace’s recently-appointed Chief Executive Officer and director, an option to purchase 380,424 shares of NeuroPace’s common stock at an exercise price of $4.39 under its 2023 Inducement Plan.

• NeuroPace to Report Second Quarter 2023 Financial Results on August 8, 2023

  7/18/2023

  NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the second quarter of 2023 after market close on Tuesday August 8, 2023.

• NeuroPace Announces CEO Transition

  6/28/2023

  NeuroPace, Inc. announced the appointment of Mr. Joel Becker as NeuroPace President & CEO and member of the Board of Directors effective July 10, 2023.

• NeuroPace Announces Addition of Kelley Nicholas as Vice President, Sales

  5/24/2023

  NeuroPace, Inc. announced the appointment of Ms. Kelley Nicholas as Vice President of Sales effective May 22, 2023.

• NeuroPace Reports First Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

  5/4/2023

  NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, reported financial results for the first quarter ended March 31, 2023.